30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: Alphatec Spine

$53.2MM, +4% (U.S. $34.5MM, +6%; ex-U.S. $18.6MM, +1%)

  • Less-invasive solutions +16%, driven by strong global uptake of Illico MIS
  • Biologics +25%
  • Initiated U.S. beta launch of Arsenal fixation system: ergonomic instrumentation + low-profile implants for complex degenerative conditions, with 92 different instruments delivered in 30 configurations; expecting to complete 150-200 cases during beta; system competes in a broader set of procedures than Zodiac, which presently represents >50% of revenue; full launch slated for 1Q15